North America’s pharma industry saw a drop of 15.7% in deal activity during February 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 70 pharma industry deals worth $29.37bn were announced for the region in February 2019, against the 12-month average of 83 deals.
Of all the deal types, venture financing saw most activity in February 2019 with 49 transactions, representing a 70% share for the region.
In second place was M&A with 16 deals, followed by private equity deals with five transactions, respectively capturing a 22.9% and 7.1% share of the overall deal activity for the month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, M&A was the leading category in North America’s pharma industry with $27.72bn, while venture financing and private equity deals totalled $1.04bn and $610.6m, respectively.
North America pharma industry deals in February 2019: Top deals
The top five pharma deals accounted for 94% of the overall value during February 2019.
The combined value of the top five pharma deals stood at $27.6bn, against the overall value of $29.37bn recorded for the month. The top announced pharma deal tracked by GlobalData in February 2019 was Danaher‘s $21.4bn asset transaction with General Electric.
In second place was the $4.3bn acquisition of Spark Therapeutics by F. Hoffmann-La Roche and in third place was Ipsen‘s $1.3bn acquisition of Clementia Pharmaceuticals.
The $300m private equity deal with Kadiant by TPG Capital and Vida Ventures and Merck Sharp & Dohme’s acquisition of Immune Design for $300m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
